BMO Upgrades Biogen (BIIB) to Market Perform Following Positive Trial Results for Oral BG-12
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $216.78 +1.13%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
An analyst at BMO Capital upgraded shares of Biogen (NASDAQ: BIIB) from Underperform to Market Perform Monday afternoon. The firm boosted its price target on the stock from $57 to $79.
The upgrade follows earlier news that Biogen's Phase 3 trial investigating its oral BG-12 in multiple sclerosis met primary and all secondary endpoints.
Biogen shares are up more than 6 percent Monday, last trading around $77.80.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
The upgrade follows earlier news that Biogen's Phase 3 trial investigating its oral BG-12 in multiple sclerosis met primary and all secondary endpoints.
Biogen shares are up more than 6 percent Monday, last trading around $77.80.
For more ratings news on Biogen click here and for the rating history of Biogen click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
- Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
Create E-mail Alert Related Categories
UpgradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
